Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27688707 | 0.87 | CASP6 (0.46) | CASP6HCAR3TSHRLMNATDP1 | |
| SCHEMBL27502068 | 0.84 | CASP6 (0.50) | CASP6POLBHCAR3TSHRLMNA | |
| SCHEMBL27826347 | 0.84 | MRGPRX4 (0.44) | CASP6MRGPRX4POLBHCAR3TSHR | |
| SCHEMBL16369681 | 0.81 | KDM4E (0.50) | CASP6POLBHCAR3TSHRLMNA | |
| SCHEMBL27751980 | 0.81 | POLB (0.50) | CASP6POLBHCAR3TSHRLMNA | |
| SCHEMBL1538816 | 0.80 | LMNA (0.58) | CASP6POLBHCAR3TSHRLMNA | |
| SCHEMBL10487799 | 0.80 | TSHR (0.52) | CASP6MRGPRX4POLBHCAR3TSHR | |
| SCHEMBL27313061 | 0.80 | TSHR (0.58) | CASP6MRGPRX4POLBHCAR3TSHR | |
| SCHEMBL27703640 | 0.80 | CASP6 (0.46) | CASP6POLBHCAR3TSHRLMNA | |
| SCHEMBL27751981 | 0.79 | ALDH1A1 (0.47) | CASP6HCAR3LMNATDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100484935-C | benzimidazole derivatives as factor Xa inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-05-06 | — | — | CN | disclosed |
| US-20080312215-A1 | Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| CN-101139346-A | Benzimidazole-derivatives as factor Xa inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-03-12 | — | — | CN | disclosed |
| WO-2007002742-A1 | SUBSTITUTED [1,4]-DIAZEPANES AS CXCR3 ANTAGONISTS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | PHARMACOPEIA, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| CN-1791598-A | benzimidazole derivatives as factor Xa inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312215-A1 | Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders | CXCR3, CXCR1, CX3CR1 | CASP6 3467/4885MRGPRX4 48/4885POLB 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.